FPGemelliIRCCS
Rome, 00168, Italy
NCT Number: NCT05638971
Peripheral intravenous (PIV) therapy is one of the most common invasive procedures performed in hospitals. PIV failures often occur when fluids leak out of the vein into surrounding tissue. This failure is usually called infiltration if the leakage involves non-vesicant solutions or extravasation in case of vesicant solutions. In this clinical study both infiltration and extravasation events are indicated by the term "infiltration".
neonatal intensive care unit patients are an high-risk population for infiltration due to their intrinsic characteristic: poor and fragile vein asset, frequent and uncontrolled movements, need for prolonged intravenous drug and fluid administration. Current nursing practice involves regular PIV site assessments for continuous infusions; particular attention is payed to the identification of swelling, pain, redness, warmth, or coolness. As infiltration represents a leading cause of iatrogenic injury, an early identification, an early identification can minimize its consequences.
The ivWatch Model 400 is a device that assists medical professionals in monitoring patients for PIV infiltrations using an optical sensor. This device received FDA clearance and European Conformity Mark for use in the adult and pediatric age groups. ivWatch enhanced the Model 400 to support a new disposable electronic sensor (SmartTouch sensor). In this study, the SmartTouch Sensor will be tested in a neonatal population in a NICU setting. The new sensor design includes optical components in the sensor package, similar to a typical pulse oximeter.
Primary study objective is to investigate whether the ivWatch SmartTouch sensor may be helpful in early identification of any kind of infiltration, if compared with our current standards of care.
Looking for future studies?
Notify Me0 day–28 day
All sexes
Interventional
Not applicable
Rome, 00168, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The second half sample size PIVC will be enrolled into an alarming group. ivWatch will monitor the PIVC insertion site collecting data and sending visual and auditory notifications of any infiltration. The goals of the study on the alarming group are: a) to estimate the notification rate (the number of detected infiltration in the studied period; b) to evaluate the extension and severity of the detected infiltration at the time of the notification, so to gather if ivWatch is helpful in early diagnosis
Other names: Sensor Allarm Group
Time frame: through study completion, an average of 30 hours
How many times the ivWatch detect infiltrations before nurses. The degree of injury is calculated on the Millian scale.
Time frame: through study completion, an average of 30 hours
time to detection (nurse vs ivWatch) and notification rate of the ivWatch
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Other
Optical Detection Infiltration/Extravasation in Neonates, a Continuous Monitoring for Peripheral Venous Accesses.
Acronym: ODINE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06615063
Extravasation, Extravasation Injury
Rawalpindi, Punjab Province, Pakistan
View Trial DetailsNCT02598609
Catheter-related Bloodstream Infection (CRBSI) Nos, Cross Infection
Strasbourg, Alsace, France
View Trial DetailsNCT04321447
Extravasation Injury
View Trial DetailsNCT07524608
Cardiovascular Diseases, Embolism and Thrombosis
Gothenburg, Sweden
View Trial Details